Systematic review of ablative therapy for the treatment of renal allograft neoplasms

Table 2 Summary of the characteristics of the case reports and the case series of kidney allograft neoplasms treated by ablative therapy¹

Variables	Range or number
Neoplasms	100
Imaging-based diagnosis
RCC	94
Cystic mass	4
Oncocytoma	1
Not available	1
Localization
Interpolar	16
Lower pole	12
Upper pole	10
Not available	62
Growth pattern
Endophytic	27
Exophytic	16
Mixed exo-endophytic	5
Not available	52
Size
Maximal diameter (mm)	5-55
Maximal diameter 0-20 mm	37
Maximal diameter 21-30 mm	26
Maximal diameter 31-40 mm	9
Maximal diameter > 40 mm	1
Not available	27
Histology-based diagnosis
Papillary RCC	48
Clear cell RCC	20
Chromophobe RCC	2
Tubulo-papillary RCC	2
Tubulo-cystic RCC	1
Mixed clear cell and papillary RCC	1
RCC not otherwise specified	17
Oncocytoma	1
Indeterminate	1
Not available	7
Fuhrman grading score
Grade I	10
Grade II	24
Grade I-II	3
Grade III	1
Not available	62
AJCC TNM classification
T1a N0 M0	91
T1b N0 M0	2
Not available	7
Ablative treatment
RFA	78
CA	15
MWA	3
HIFU	3)
IRE	1/100 (1)

¹Summaries based on individual cases should not be considered as an estimate of the “real world”. RCC: Renal cell carcinoma; AJCC: American Joint Committee on Cancer; TNM: Tumor nodes metastasis; RFA: Radiofrequency ablation; CA: Cryoablation; MWA: Microwave ablation; HIFU: High-intensity focused ultrasound; IRE: Irreversible electroporation.